Is AbbVie Inc. (ABBV) a Buy, Sell, or Hold?
NYSE : ABBV
AbbVie Inc.
$266.19 USD
$9.28 (3.61%)
- Volume
- 4.09M
- Average Volume
- 6.98M
- Market Capitalization
- $470.3B
- P/E Ratio
- 130.52
- Dividend Yield
- 2.57%
- Price Target
- $279.00
- Year High
- $266.93
- Year Low
- $187.62
- Day High
- —
- Day Low
- —
- Payout Ratio
- $3.25
- Current Ratio
- $0.80
Company Overview
NYSE
Robert A. Michael
Drug Manufacturers - General
Healthcare
ABBV
57000
US
USD
Liquidity Metrics
2.65
0.80
0.68
0.22
3.25
Sales & Valuation
$61.16B
7.49
17.17
22.54
11.76
Profitability
$2.37
$4.23B
5.79%
9.51%
68.01%
2.67%
P/E Metrics
130.52
-9.89
-9.89
Analyst Price Target & Rating
$279.00
$300.00
$235.00
2/5
41 Analysts
-4.59%
Financial Health Scores
2.94
7/9
-$8.57B
$136.46B
$108.96B
$8.88B
Key Metrics (TTM)
$517.39B
8.24
30.58
0.80
68.01%
10.29%
0.80%
4.60%
$26.75
-493 days
Company Executives
| Name | Title |
|---|---|
| Nicholas J. Donoghoe | Executive Vice President and Chief Business & Strategy Officer |
| Elizabeth Shea | Senior Vice President of Investor Relations |
| Perry C. Siatis | Executive Vice President, General Counsel & Secretary |
| Wulff-Erik von Borcke | Senior Vice President & President of Oncology |
| Linda Ray | Senior VP & Chief Information Officer |
| Demetris D. Crum | Executive Vice President & Chief Human Resources Officer |
| Azita Saleki-Gerhardt | Executive Vice President & Chief Operating Officer |
| Roopal Thakkar | Executive Vice President of Research and Development & Chief Scientific Officer |
| Jeffrey Ryan Stewart | Executive Vice President & Chief Commercial Officer |
| Robert A. Michael | Chief Executive Officer & Chairman of the Board |
| Scott T. Reents | Executive Vice President & Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About AbbVie Inc. (NYSE:ABBV) Stock
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals wi ... th chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
2026-07-28 14:11:08
AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st
2026-07-28 13:09:56
AbbVie (NYSE:ABBV | ABBV Price Prediction) enters its July 31 Q2 earnings report with a 2.62% dividend yield, raised earnings guidance, and two blockbuster drugs growing above 20%.
2026-07-28 11:55:49
DGRO markets itself as a sleepy dividend fund, but its rulebook quietly funnels money toward mega-cap tech, and the compounding math behind that combination may rewrite which ETF actually wins over the next decade.
Should You Buy AbbVie Stock Hand Over Fist Before July 31?
2026-07-27 18:45:00
After reporting an earnings beat last quarter, AbbVie could once again beat expectations in the second quarter, although management recently warned about the negative impact of one-time charges. Shares in the pharmaceutical company have rallied recently, so investors could use any negative aspect of the earnings release as an excuse to take profits.
Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck
2026-07-27 11:40:30
The 2026 Social Security COLA came in at just 2.8%, which is barely keeping pace with a grocery bill, let alone replacing a paycheck.
Sarepta names former Abbvie president as CEO as Ingram retires
2026-07-27 09:19:09
Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO Michael Severino its chief executive, effective July 28. The longtime AbbVie executive, will succeed Doug Ingram.
Gabelli Funds LLC Sells 25,600 Shares of AbbVie Inc. $ABBV
2026-07-27 03:55:59
Gabelli Funds LLC reduced its position in AbbVie Inc. (NYSE: ABBV) by 31.5% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 55,613 shares of the company's stock after selling 25,600 shares during the period. Gabelli Funds LLC's holdings in AbbVie were worth $12,095,000 as of
Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?
2026-07-26 05:47:00
These two companies are pharmaceutical giants. Both seem somewhat overvalued at recent levels.
Frequently Asked Questions
-
What is the current AbbVie Inc. (ABBV) stock price?
-
AbbVie Inc.(NYSE:ABBV) stock price is $266.19 in the last trading session. During the trading session, ABBV stock reached the peak price of $266.93 while $187.62 was the lowest point it dropped to. The percentage change in ABBV stock occurred in the recent session was 3.61% while the dollar amount for the price change in ABBV stock was $9.28.
-
ABBV's industry and sector of operation?
-
The NYSE listed ABBV is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of ABBV?
-
Nicholas J. Donoghoe | Executive Vice President and Chief Business & Strategy Officer
Elizabeth Shea | Senior Vice President of Investor Relations
Perry C. Siatis | Executive Vice President, General Counsel & Secretary
Wulff-Erik von Borcke | Senior Vice President & President of Oncology
Linda Ray | Senior VP & Chief Information Officer -
How many employees does ABBV have?
-
Number of ABBV employees currently stands at 57000. ABBV operates from 1 North Waukegan Road, North Chicago, IL 60064-6400, US.
-
Link for ABBV official website?
-
Official Website of ABBV is: https://www.abbvie.com
-
How do I contact ABBV?
-
ABBV could be contacted at phone #847 932 7900 and can also be accessed through its website. ABBV operates from 1 North Waukegan Road, North Chicago, IL 60064-6400, US.
-
How many shares of ABBV are traded daily?
-
The average number of ABBV shares traded daily for last 3 months was 6.98M.
-
What is the market cap of ABBV currently?
-
The market value of ABBV currently stands at $470.3B with its latest stock price at $266.19